irinotecan has been researched along with chitosan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Gaud, R; Shende, P | 1 |
| Duan, K; Huang, J; Li, Y; Liu, S; Tang, X; Wang, D; Yu, J; Zhang, X | 1 |
| Guo, M; Hou, J; Lu, Y; Rong, WT; Wang, DF; Wang, Y; Xu, Q; Yu, SQ | 1 |
| Amini, M; Atyabi, F; Azhdarzadeh, M; Dinarvand, M; Ghasemi, Z; Mollarazi, E; Sayari, E | 1 |
| Cheng, G; Gao, Y; Liu, J; Liu, Y; Piao, H; Tang, B; Tian, Y; Wang, L; Xu, C; Zou, M | 1 |
| Atyabi, F; Dinarvand, M; Dinarvand, R; Esmaeili, A; Kiani, M; Mirzaie, Z; Mirzazadeh, F; Soleimani, M | 1 |
| Amini, M; Atyabi, F; Azhdarzadeh, M; Dinarvand, R; Esfandyari-Manesh, M; Hosseinzadeh, H; Mirzaie, ZH; Ostad, SN; Vafaei, SY; Varnamkhasti, BS | 1 |
| Agarwal, P; He, X; Lu, X; Wang, H; Xu, RX; Yu, J; Zhao, S | 1 |
| Gao, Z; Li, Z; Wang, P; Yan, J | 1 |
| Afkham, A; Afkham, NM; Aghebati-Maleki, L; Ahmadi, M; Akbarzadeh, P; Dolati, S; Jadidi-Niaragh, F; Sadreddini, S; Siahmansouri, H; Younesi, V; Yousefi, M | 1 |
| Ahmad, N; Ahmad, R; Alam, MA; Jalees Ahmad, F; Umar, S | 1 |
| Li, Y; Wang, H; Wu, D; Wu, R; Xu, S; Yang, G; Zhang, X; Zhu, L | 1 |
| Chan, LY; Chen, JP; Chuang, CC; Hsu, PW; Lan, YH; Lu, WT; Lu, YJ | 1 |
| Ebrahimnejad, P; Jahangiri, M; Sharifi, F | 1 |
| Li, Y; Wu, D; Xu, S; Yan, Q; Yang, G; Yang, Y; Zhang, W; Zhu, L | 1 |
| Bhaskaran, NA; Cheruku, S; Jitta, SR; Kumar, L; Kumar, N | 1 |
| Ji, W; Li, Y; Liu, H; Wu, D; Yang, G; Zhang, W; Zhao, Z | 1 |
| Li, J; Qin, J; Sun, M; Wang, D; Zhen, Y | 1 |
| Lin, WJ; Pai, FT | 1 |
19 other study(ies) available for irinotecan and chitosan
| Article | Year |
|---|---|
Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Chitosan; Cholesterol; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Stability; Electrochemistry; Freeze Fracturing; Gelatin; Irinotecan; Liposomes; Phosphatidylcholines | 2009 |
Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin.
Topics: Camptothecin; Cations; Chitosan; Drug Carriers; Irinotecan; Micelles; Nanostructures; Particle Size; Polyesters; Surface Properties | 2010 |
Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
Topics: Absorption; Animals; Caco-2 Cells; Calorimetry, Differential Scanning; Camptothecin; Cell Death; Chitosan; Coated Materials, Biocompatible; Coumarins; Enterocytes; HT29 Cells; Humans; Intestines; Irinotecan; Kinetics; Lactic Acid; Male; Nanoparticles; Particle Size; Perfusion; Permeability; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Rhodamine 123; Spectroscopy, Fourier Transform Infrared; Static Electricity; X-Ray Diffraction | 2013 |
MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Camptothecin; Cell Survival; Chitosan; CHO Cells; Cricetinae; Cricetulus; Drug Carriers; Esters; HT29 Cells; Humans; Irinotecan; Molecular Targeted Therapy; Mucin-1; Nanoparticles | 2014 |
Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chitosan; Irinotecan; Macromolecular Substances; Male; Mice; Mice, Inbred BALB C; Micelles; Particle Size; Prodrugs; Rats; Rats, Sprague-Dawley; Solubility; Xenograft Model Antitumor Assays | 2015 |
Oral delivery of nanoparticles containing anticancer SN38 and hSET1 antisense for dual therapy of colon cancer.
Topics: Administration, Oral; Animals; Camptothecin; Cell Line, Tumor; Chitosan; Colonic Neoplasms; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Stability; Histone-Lysine N-Methyltransferase; Humans; Irinotecan; Mice; Nanoparticles; Oligonucleotides, Antisense; Spectroscopy, Fourier Transform Infrared; Xenograft Model Antitumor Assays | 2015 |
Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles.
Topics: Animals; Apoptosis; Aptamers, Nucleotide; Calorimetry, Differential Scanning; Camptothecin; Cell Line, Tumor; Cell Survival; Chitosan; Cricetinae; Drug Carriers; Drug Liberation; Humans; Hyaluronic Acid; Irinotecan; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Mucin-1; Nanoparticles; Particle Size; Protein Corona | 2015 |
Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Endocytosis; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Intracellular Space; Irinotecan; Lactic Acid; Male; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spheroids, Cellular; Tissue Distribution | 2015 |
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stomach Neoplasms | 2017 |
Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
Topics: Antineoplastic Agents; Cadherins; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chitosan; Claudin-1; Drug Delivery Systems; Humans; Irinotecan; Male; Nanoparticles; Prostatic Neoplasms; RNA, Small Interfering; Snail Family Transcription Factors | 2018 |
Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Brain; Caco-2 Cells; Camptothecin; Chitosan; Drug Carriers; Humans; Intestinal Absorption; Irinotecan; Lactic Acid; Male; MCF-7 Cells; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2018 |
Superparamagnetic chitosan nanocomplexes for colorectal tumor-targeted delivery of irinotecan.
Topics: Animals; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Colorectal Neoplasms; Drug Carriers; Drug Liberation; Drug Stability; Female; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Magnetic Iron Oxide Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polyelectrolytes; Polyglutamic Acid; Surface Properties; Tissue Distribution; Topoisomerase I Inhibitors | 2020 |
Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy.
Topics: Blood Proteins; Cell Line, Tumor; Chitosan; Drug Delivery Systems; ErbB Receptors; Gene Transfer Techniques; Glioblastoma; Graphite; Humans; Hydrogels; Irinotecan; Membrane Proteins; Neoplasm Proteins; RNA, Small Interfering | 2020 |
Synthesis of novel polymeric nanoparticles (methoxy-polyethylene glycol-chitosan/hyaluronic acid) containing 7-ethyl-10-hydroxycamptothecin for colon cancer therapy:
Topics: Caco-2 Cells; Chitosan; Humans; Hyaluronic Acid; Irinotecan; Polyethylene Glycols | 2021 |
A biocompatible superparamagnetic chitosan-based nanoplatform enabling targeted SN-38 delivery for colorectal cancer therapy.
Topics: Animals; Antineoplastic Agents; Chitosan; Colorectal Neoplasms; Drug Delivery Systems; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Mice; Mice, Nude; Nanoparticles | 2021 |
Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: Preparation, in-vitro and in-vivo evaluations.
Topics: Animals; Chitosan; Colonic Neoplasms; Drug Carriers; Irinotecan; Lipids; Liposomes; Male; Nanoparticles; Particle Size; Rats; Rats, Wistar; Tissue Distribution | 2022 |
Gold nanorods-loaded chitosan-based nanomedicine platform enabling an effective tumor regression in vivo.
Topics: Cell Line, Tumor; Chitosan; Gold; Irinotecan; Nanomedicine; Nanotubes | 2023 |
A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Topics: Animals; Camptothecin; Cell Line, Tumor; Chitosan; Hyaluronic Acid; Irinotecan; Mice; Neoplasms; Polymers; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Synergistic cytotoxicity of irinotecan combined with polysaccharide-based nanoparticles for colorectal carcinoma.
Topics: Chitosan; Colorectal Neoplasms; Fluorescein-5-isothiocyanate; Humans; Irinotecan; Nanoparticles | 2023 |